For all press and media enquiries please contact mediarelations@chiesi.com
Giuseppe Accogli is a successful Executive Leader with 25 years of international experience in the Med-tech sector of reputed and complex companies such as Tyco Healthcare (Covidien), Baxter and Medtronic. “As CEO, I strive to enable our leaders, people and partners to achieve even greater success…
Chiesi Group has been named on Carbon Disclosure Project’s Climate Change A List for its commitment to climate action and transparency. The Group has also received from Cerved Rating Agency the AA ESG rating with an overall score of 75.1 out of 100. According to the independent rating agency, Chiesi…
- Transaction expands Chiesi’s rare disease medicine portfolio - All cash acquisition at US$14.50 per ADS, plus Contingent Value Rights of up to an additional US$2.50 per ADS based on certain Filsuvez® milestones being achieved - Total Transaction value of up to US$1.48 Billion with upfront…
Following the recent statements appeared in the media, Chiesi Farmaceutici would like to reiterate that the Company is not involved in the events concerning the company Holostem Terapie Avanzate s.r.l. ("Holostem"). The investments in support of Holostem have been carried out directly by Valline…
The Manifesto was signed with the CGIL, CISL, and UIL trade unions on the International Day for the Elimination of Violence Against Women. The goal is to ensure that all Group employees adopt respectful and considerate behaviour. Parma (Italy) November 28, 2022 – On the International Day for the…
The new center of excellence for the development and production of biologic drugs, currently under construction, will be built in Parma in the area of the production plant; Construction of the building is rapidly progressing, and it is scheduled to receive its first technological installations by…
The new Digital Health Solution aims at offering patients and healthcare professionals a comprehensive set of services and solutions targeted at improving outcomes for chronic respiratory diseases. Parma (Italy) and Crystal Lake (Illinois) October 18 th, 2022 – Chiesi Group, the international…
The Group has increased its B-Impact score by 16.3 points, with 103.8 out of 200 compared to its first certification in 2019; The recertification process by B Lab identifies further focus for action and continuous improvement. Parma (Italy) September 22 nd, 2022 – The B Corp movement, established to…
Chronic obstructive pulmonary disease, or COPD, is the third leading cause of death in the world, causing 300,000 annual deaths in Europe 1 At the European Respiratory Society Congress, Chiesi Group presents an additional option to address the needs of COPD patients: Chiesi’s extrafine triple…
You are leaving the Chiesi Corp site to access another Chiesi site. Regulatory constraints and medical practices, as well as the information published on the site you are about to visit, may change from one country to another and may not comply with current Italian legislation on the subject.
You are about to leave our website and access an external site. By continuing, you agree to leave our site.
